NASDAQ:QTRX - Nasdaq - US74766Q1013 - Common Stock - Currency: USD
7.55
-0.03 (-0.4%)
The current stock price of QTRX is 7.55 USD. In the past month the price decreased by -26.05%. In the past year, price decreased by -69.64%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
DHR | DANAHER CORP | 28.07 | 151.18B | ||
A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
WAT | WATERS CORP | 31.58 | 22.26B | ||
ICLR | ICON PLC | 14.39 | 16.63B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
RVTY | REVVITY INC | 23.23 | 13.85B | ||
AVTR | AVANTOR INC | 17.3 | 11.78B | ||
TEM | TEMPUS AI INC | N/A | 10.72B |
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 441 full-time employees. The company went IPO on 2017-12-07. The firm is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The firm's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, and NfL antibodies and NfL ELISA kits. The company also offers contract research services for customers through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. The company has completed over 2,200 projects for 480 customers using its Simoa platforms.
QUANTERIX CORP
900 Middlesex Turnpike
Billerica MASSACHUSETTS 01821 US
CEO: E. Kevin Hrusovsky
Employees: 441
Company Website: https://www.quanterix.com/
Investor Relations: https://ir.quanterix.com/
Phone: 16173019400
The current stock price of QTRX is 7.55 USD. The price decreased by -0.4% in the last trading session.
The exchange symbol of QUANTERIX CORP is QTRX and it is listed on the Nasdaq exchange.
QTRX stock is listed on the Nasdaq exchange.
11 analysts have analysed QTRX and the average price target is 18.36 USD. This implies a price increase of 143.18% is expected in the next year compared to the current price of 7.55. Check the QUANTERIX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUANTERIX CORP (QTRX) has a market capitalization of 291.20M USD. This makes QTRX a Micro Cap stock.
QUANTERIX CORP (QTRX) currently has 441 employees.
QUANTERIX CORP (QTRX) has a resistance level at 8.07. Check the full technical report for a detailed analysis of QTRX support and resistance levels.
The Revenue of QUANTERIX CORP (QTRX) is expected to grow by 13.21% in the next year. Check the estimates tab for more information on the QTRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QTRX does not pay a dividend.
QUANTERIX CORP (QTRX) will report earnings on 2025-03-17, after the market close.
QUANTERIX CORP (QTRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
The outstanding short interest for QUANTERIX CORP (QTRX) is 6.93% of its float. Check the ownership tab for more information on the QTRX short interest.
ChartMill assigns a fundamental rating of 4 / 10 to QTRX. QTRX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months QTRX reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS decreased by -2.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -12.28% | ||
ROE | -14.89% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to QTRX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -10.5% and a revenue growth 13.21% for QTRX